T-SPOT®.TB test can be used for the diagnosis of diseases simply by detecting the
presence of an effector T cell response. This is particular useful in latent or
initially subclinical diseases where there is no recoverable pathogen or reliable antibody response; and thus where conventional techniques fail. Despite the technique’s exquisite sensitivity (measurement down to the individual cell level), it is a simple and robust technique that does not require the use of specialised equipment.
T-SPOT®.TB test
A blood test for the detection of latent and active TB that performs well in immunocompromised patients.
T-SPOT®.TB test is the world’s first commercialised and regulatory approved technique, manufactured under international quality standards, to directly
measure effector T cell function.
The test can be used in the following patient applications, populations and purposes:
Preventative screening amongst immunocompromised patient groups
including:
HIV, anti-TNF α therapy, renal dialysis & transplant
Targeted testing of high risk populations including:
TB suspects, contact tracing and immigrants
Screening for at-risk populations including:
Healthcare professionals / occupational health
Definitive results within 24 hours
Quick turn-around time, reduced risk of further cross infections
